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Apolipoprotein Estudy was to identify genetic variants that confer susceptibility to chronic kidney
disease (CKD) in Japanese individuals with metabolic syndrome. The study population comprised 2150
Japanese individuals with metabolic syndrome, including 411 subjects with CKD [estimated glomerular
ﬁltration rate (eGFR) b50 mL/min/1.73m2] and 1739 controls (eGFR ≥60 mL/min/1.73m2). The genotypes for
100 polymorphisms of 80 candidate genes were determined. The chi-square test, multivariable logistic
regression analysis with adjustment for covariates, as well as a stepwise forward selection procedure
revealed that nine polymorphisms of APOE, ABCA1, PTGS1, TNF, CPB2, AGTR1, OR13G1, and GNB3 were
associated (Pb0.05) with the prevalence of CKD. Among these polymorphisms, the −219G→T polymorphism
of APOE (rs405509) was most signiﬁcantly associated with CKD in Japanese individuals with metabolic
syndrome.
© 2008 Elsevier Inc. All rights reserved.Introduction
Chronic kidney disease (CKD) is a global public health problem [1],
being the leading cause of end-stage renal disease (ESRD) as well as a
major determinant of poor cardiovascular outcome and premature
death [2,3]. Identiﬁcation of genetic markers for CKD risk is thus
important both for risk prediction and for intervention to avert future
ESRD and cardiovascular events.
Metabolic syndrome is deﬁned by a clustering of abdominal
obesity, a high serum concentration of triglycerides, a low serum
concentration of high density lipoprotein (HDL)–cholesterol, high
blood pressure, and an increased fasting blood glucose level [4]. It has
been recognized as an important risk factor for CKD [5–7] as well as
for coronary heart disease [8,9] and ischemic stroke [10,11]. Genetic
factors underlying predisposition to CKD in individuals withmetabolic
syndrome have remained largely unknown, however. Furthermore,
given the ethnic differences in lifestyle and environmental factors asa).
l rights reserved.well as in genetic background, it is important to examine genetic
variants related to CKD in individuals with metabolic syndrome in
each ethnic group.
We have now performed an association study for 100 polymorph-
isms of 80 candidate genes and CKD in 2150 Japanese individuals with
metabolic syndrome. The purpose of the present study was to identify
genetic variants that confer susceptibility to CKD among individuals
with metabolic syndrome and thereby to provide a basis for the
personalized prevention of this condition.
Results
The characteristics of the 2150 study subjects are shown in Table 1.
Age, the prevalence of hypertension, diabetes mellitus, myocardial
infarction, and ischemic stroke, as well as systolic blood pressurewere
greater, whereas BMI and the percentage of smokers were lower, in
subjects with CKD than in controls.
Comparison of allele frequencies with the chi-square test revealed
that 14 polymorphisms were related (P value of b0.05 for allele
frequency) to the prevalence of CKD (Table 2). Among these
Table 1
Characteristics of individuals with chronic kidney disease (CKD) and controls among
subjects with metabolic syndrome
Characteristic CKD Controls P
No. of subjects 411 1739
Age (years) 70.5±9.2 66.0±9.5 b0.0001
Sex (female/male, %) 37.7/62.3 39.6/60.4 0.4755
Body mass index (kg/m2) 24.6±3.6 25.2±5.8 0.0033
Current or former smoker (%) 18.5 28.6 b0.0001
Hypertension (%) 86.1 73.7 b0.0001
Systolic blood pressure (mmHg) 153±26 145±22 b0.0001
Diastolic blood pressure (mmHg) 82±15 82±14 0.6625
Hypercholesterolemia (%) 34.8 33.8 0.7062
Serum total cholesterol (mmol/L) 5.31±1.13 5.26±1.01 0.4738
Serum triglyceride (mmol/L) 2.18±1.16 2.14±1.38 0.6102
Serum HDL-cholesterol (mmol/L) 1.16±0.39 1.20±0.31 0.0805
Diabetes mellitus (%) 56.5 40.4 b0.0001
Fasting plasma glucose (mmol/L) 7.75±3.31 7.54±3.16 0.3451
Glycosylated hemoglobin (%) 6.37±1.66 6.15±1.64 0.1085
Serum creatinine (μmol/L) 146.9±167.2 62.8±12.4 b0.0001
eGFR (mL min−1 1.73 m−2) 39.3±10.5 78.7±15.4 b0.0001
End-stage renal disease (%) 5.1 0 b0.0001
Myocardial infarction (%) 34.1 25.7 0.0008
Ischemic stroke (%) 20.4 12.8 0.0001
Quantitative data are means± SD. Smoker: smoking of ≥10 cigarettes daily.
Hypertension: systolic blood pressure of ≥140 mmHg, diastolic blood pressure of
≥90 mmHg, or taking antihypertensive medication. Hypercholesterolemia: serum total
cholesterol of ≥5.72 mmol/L (220 mg/dL) or taking lipid-lowering medication. Diabetes
mellitus: fasting blood glucose of ≥6.93 mmol/L (126 mg/dL), glycosylated hemoglobin
(hemoglobin A1c) content of ≥6.5%, or taking antidiabetes medication. eGFR, estimated
glomerular ﬁltration rate.
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cantly [false discovery rate (FDR)b0.05] associated with this condi-
tion. The genotype distributions of all 14 polymorphisms (Table 2),
with the exception of the T→C (Ile347Thr) polymorphism of CPB2 in
control subjects, were in Hardy-Weinberg equilibrium both in
individuals with CKD and in controls (Supplementary Table 1); the
T→C (Ile347Thr) polymorphism of CPB2was therefore excluded from
subsequent analysis.
Multivariable logistic regression analysis with adjustment for age,
sex, and the prevalence of hypertension, diabetes mellitus, and
hypercholesterolemia revealed that the −219G→T polymorphism of
APOE (dominant, recessive, and additive 2 models), the G→A
(Ala163Thr) polymorphism of AGTR1 (dominant and additive 1
models), the C→T polymorphism of PTGS1 (recessive and additive 2
models), the −863C→A polymorphism of TNF (dominant and additive
1 models), the G→A (Ala147Thr) polymorphism of CPB2 (dominant
model), the 2583A→G (Ile823Met) (recessive and additive 2 models)
and −14C→T (recessive and additive 2 models) polymorphisms of
ABCA1, the 1429C→T polymorphism of GNB3 (recessive and additive
2 models), and the A→G (Ile132Val) polymorphism of OR13G1
(dominant and additive 2 models) were signiﬁcantly (Pb0.05)
associated with the prevalence of CKD (Table 3). The variant T allele
of APOE, A allele of AGTR1, T allele of PTGS1, T allele of the −14C→T
polymorphism of ABCA1, and G allele of OR13G1 were risk factors for
CKD, whereas the variant A allele of TNF, A allele of CPB2, G allele of
the 2583A→G (Ile823Met) polymorphism of ABCA1, and T allele of
GNB3 were protective against this condition.
Finally, we performed a stepwise forward selection procedure to
examine the effects of genotypes for the nine polymorphisms
associated with CKD by multiple logistic regression analysis as well
as of age, sex, and the prevalence of hypertension, diabetes mellitus,
and hypercholesterolemia on CKD (Table 4). Age, diabetes mellitus,
hypertension, APOE genotype (recessive model), ABCA1 genotype (the
−14C→T polymorphism, recessive model), PTGS1 genotype (recessive
model), TNF genotype (dominant model), CPB2 genotype (dominant
model), AGTR1 genotype (dominant model), OR13G1 genotype
(dominant model), GNB3 genotype (recessive model), and ABCA1genotype [the 2583A→G (Ile823Met) polymorphism, recessive
model], in descending order of statistical signiﬁcance, were signiﬁcant
(Pb0.05) and independent determinants of CKD.
Discussion
We examined the possible relations of 100 polymorphisms in 80
candidate genes to the prevalence of CKD in 2150 Japanese individuals
with metabolic syndrome. Our results show that the −219G→T
polymorphism of APOE was signiﬁcantly associated with CKD in such
individuals, with the variant T allele representing a risk factor for this
condition.
Apolipoprotein E (APOE) is a structural component of both
chylomicrons and very low density lipoprotein remnants, and it is
responsible for the binding and uptake of these particles by the low
density lipoprotein (LDL) receptor and LDL receptor–like protein
[12,13]. Three common alleles (ɛ2, ɛ3, and ɛ4) of APOE encode the
three major isoforms (E2, E3, and E4) of APOE, which differ at amino
acid positions 112 and 158. Allelic variation of APOE accounts for
interindividual variability in total cholesterol and LDL-cholesterol
concentrations, with studies in human populations having demon-
strated associations of the ɛ4 and ɛ2 alleles with increased and
decreased LDL-cholesterol levels, respectively [14–16]. The relation of
APOE polymorphisms to coronary heart disease or myocardial
infarction has been extensively investigated, with the ɛ4 allele having
been associated with these conditions in many studies [17–19]. A
meta-analysis of 15,492 subjects with coronary heart disease and
32,965 controls pooled from 48 studies revealed that, compared with
individuals with the ɛ3/ɛ3 genotype, carriers of the ɛ4 allele had a
higher risk for coronary heart disease (odds ratio, 1.42), whereas the
ɛ2 allele was not associated with risk for this condition [20]. The ɛ4
allele of APOE is thus an important risk factor for coronary heart
disease. In a prospective cohort study of 3859 African American and
10,661 white adults with a median follow-up time of 14 years, the ɛ2
allele moderately increased and the ɛ4 allele reduced the risk of CKD
progression [21]. This study suggested that APOE variation predicts
CKD progression independently of diabetes, race, as well as lipid and
nonlipid risk factors, and that nonlipid pathways, such as cellular
mechanisms of kidney remodeling, may contribute to the association
of APOE alleles with progression of CKD [21]. In Japanese cohorts, the
ɛ4 allele of APOE was also protective against the progression of
diabetic nephropathy [22], whereas the ɛ2 allele was associated with
an increased prevalence of ESRD [23]. These various observations
implicate APOE as a candidate susceptibility gene for CKD as well as
coronary heart disease, although the risk alleles differ between these
conditions.
The −219G→T polymorphism of APOE was previously associated
with myocardial infarction in men in France and Northern Ireland,
with the T allele representing a risk factor for this condition [24]. The T
allele of this polymorphism was also shown to be a risk factor for
coronary heart disease in low-risk Japanese men [25]. We have now
shown that the −219G→T polymorphism of APOE was signiﬁcantly
associated with the prevalence of CKD in individuals with metabolic
syndrome, with the T allele representing a risk factor for CKD.
Consistent with its location in the promoter region of APOE, the
−219G→T polymophism was previously shown to be associated with
the plasma concentration of APOE, with the T allele conferring a
reduced APOE concentration, but this polymorphismwas found not to
be related to plasma lipid proﬁle [24]. The deleterious inﬂuence of the
T allele on coronary heart disease and CKD therefore cannot be
explained by its effect on the circulating level of APOE. Although an
abnormality in lipoprotein metabolism may play an important role in
the acceleration of atherosclerosis and the development of global
glomerulosclerosis [26,27], the mechanism underlying the association
of the −219G→T polymorphism of APOE with CKD remains to be
determined.
Table 2
Genotype distributions of polymorphisms related (Pb0.05 for allele frequency) to chronic kidney disease (CKD) by the chi-square test among individuals with metabolic syndrome
Gene symbol Polymorphism dbSNP CKD Controls P (genotype) P (allele frequency) FDR
APOE −219G→T rs405509 0.0016 0.0004 0.043
GG 23 (5.6) 148 (8.5)
GT 149 (36.3) 744 (42.8)
TT 239 (58.1) 847 (48.7)
AGTR1 G→A (Ala163Thr) rs12721226 0.0044 0.0045 0.223
GG 408 (99.3) 1738 (99.9)
GA 3 (0.7) 1 (0.1)
AA 0 (0) 0 (0)
PTGS1 C→T rs883484 0.0349 0.0141 0.276
CC 143 (34.8) 684 (39.3)
CT 191 (46.5) 811 (46.7)
TT 77 (18.7) 244 (14.0)
TNF −863C→A rs1800630 0.0588 0.0194 0.276
CC 320 (77.9) 1254 (72.1)
CA 85 (20.7) 449 (25.8)
AA 6 (1.4) 36 (2.1)
CPB2 G→A (Ala147Thr) rs3742264 0.0666 0.0196 0.276
GG 249 (60.6) 957 (55.0)
GA 142 (34.6) 657 (37.8)
AA 20 (4.9) 125 (7.2)
UCP2 −866G→A rs659366 0.0605 0.0214 0.276
GG 97 (23.6) 479 (27.5)
GA 204 (49.6) 881 (50.7)
AA 110 (26.8) 379 (21.8)
LRP8 T→G (Asp46Glu) rs3820198 0.0547 0.0261 0.276
TT 130 (31.6) 492 (28.3)
TG 210 (51.1) 855 (49.2)
GG 71 (17.3) 392 (22.5)
ABCA1 2583A→G (Ile823Met) rs4149313 0.0886 0.0275 0.276
AA 68 (16.5) 242 (13.9)
AG 195 (47.5) 773 (44.5)
GG 148 (36.0) 724 (41.6)
ABCA1 −14C→T rs1800977 0.0306 0.0301 0.276
CC 217 (52.8) 985 (56.7)
CT 156 (38.0) 652 (37.5)
TT 38 (9.2) 101 (5.8)
GNB3 1429C→T rs5446 0.0699 0.0311 0.276
CC 287 (69.8) 1136 (65.4)
CT 115 (28.0) 528 (30.4)
TT 9 (2.2) 74 (4.2)
OR13G1 A→G (Ile132Val) rs1151640 0.0660 0.0344 0.276
AA 266 (15.3) 266 (15.3)
AG 782 (45.0) 782 (45.0)
GG 691 (39.7) 691 (39.7)
SERPINE1 A→G (Tyr243Cys) rs13306846 0.0361 0.0361 0.276
AA 409 (99.5) 1738 (99.9)
AG 2 (0.5) 1 (0.1)
GG 0 (0) 0 (0)
CPB2 T→C (Ile347Thr) rs1926447 0.0223 0.0442 0.276
TT 9 (2.2) 46 (2.7)
TC 122 (29.7) 404 (23.2)
CC 280 (88.1) 1289 (74.1)
APOA5 −3A→G rs651821 0.1433 0.0488 0.276
AA 170 (41.4) 636 (36.6)
AG 187 (45.5) 827 (47.6)
GG 54 (13.1) 275 (15.8)
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AGTR1, OR13G1, and GNB3 were also related to the prevalence of CKD
in individuals with metabolic syndrome, with none of these
polymorphisms having previously been shown to be associated with
CKD. The −14C→T and 2583A→G (Ile823Met) polymorphisms of
ABCA1 have been shown to affect the plasma level of HDL-cholesterol
in Japanese [28] and Turkish [29] populations. The T allele of the
1429C→T polymorphism of GNB3 has also been shown to be a risk
factor for the development of hypercholesterolemia in Japanese males
[30]. The C→T polymorphism of PTGS1 [31], the G→A (Ala147Thr)
polymorphism of CPB2 [32], and the A→G (Ile132Val) polymorphism
of OR13G1 [33] were previously found to be associated with
myocardial infarction or coronary heart disease. Although the
1166A→C polymorphism of AGTR1 [34,35] and the −308G→Apolymorphism of TNF [36,37] were shown to be associated with
CKD, the G→A (Ala163Thr) polymorphism of AGTR1 and the
−863C→A polymorphism of TNF have not previously been associated
with this condition in a prospective cohort or case-control study. The
A allele of the −863C→A polymorphism of TNF was shown to be
protective against the development of coronary artery disease in
Japanese men without type 2 diabetes [38].
Our study has several limitations: (1) We used eGFR instead of
directly measured GFR to deﬁne CKD. (2) We were not able to obtain
information about the underlying renal disease in all subjects with
CKD. Such information can be obtained by detailed clinical examina-
tion, including renal biopsy, but such diagnostic procedures are not
considered feasible for a study whose subjects are recruited from the
general population. (3) It is possible that one or more of the
Table 3
Multivariable logistic regression analysis of polymorphisms related to chronic kidney disease for individuals with metabolic syndrome
Gene symbol Polymorphism Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
APOE −219G→T 0.0234 1.72 (1.10–2.80) 0.0006 1.48 (1.18–1.86) 0.1675 0.0049 1.98 (1.25–3.27)
AGTR1 G→A (Ala163Thr) 0.0275 13.3 (1.6–271.7) 0.0275 13.3 (1.6–271.7)
PTGS1 C→T 0.1805 0.0073 1.50 (1.11–2.00) 0.6198 0.0084 1.55 (1.12–2.14)
TNF −863C→A 0.0150 0.72 (0.55–0.93) 0.2508 0.0268 0.74 (0.56–0.96) 0.1920
CPB2 G→A (Ala147Thr) 0.0236 0.77 (0.61–0.96) 0.1003 0.0656 0.0510
UCP2 −866G→A 0.1797 0.1016 0.3890 0.0679
LRP8 T→G (Asp46Glu) 0.3999 0.0512 0.8432 0.0714
ABCA1 2583A→G (Ile823Met) 0.0628 0.0181 0.76 (0.60–0.95) 0.2688 0.0148 0.66 (0.47–0.92)
ABCA1 −14C→T 0.1149 0.0047 1.79 (1.18–2.67) 0.4366 0.0034 1.86 (1.22–2.80)
GNB3 1429C→T 0.2074 0.0407 0.47 (0.22–0.92) 0.4960 0.0352 0.46 (0.21–0.90)
OR13G1 A→G (Ile132Val) 0.0308 1.47 (1.05–2.10) 0.2748 0.0532 0.0306 1.50 (1.05–2.19)
SERPINE1 A→G (Tyr243Cys) 0.0923 0.2417 0.2362 0.0923
APOA5 −3A→G 0.1443 0.2995 0.2392 0.1598
OR, odds ratio; CI, conﬁdence interval. Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension, diabetes mellitus,
and hypercholesterolemia. P values of b0.05 are shown in bold.
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linkage disequilibriumwith other polymorphisms in the same gene or
in other nearby genes that are actually responsible for the develop-
ment of this condition. (4) The functional relevance of the identiﬁed
polymorphisms to gene transcription or to protein structure or
function was not determined in the present study.
In conclusion, our present results suggest that the −219G→T
polymorphismof APOE is signiﬁcantly associatedwith CKD in Japanese
individuals with metabolic syndrome. Validation of our ﬁndings will
require their replication with independent subject panels.
Materials and methods
Study population
The study population comprised 2150 unrelated Japanese indivi-
duals (1306 men, 844 women) who either visited outpatient clinics of
or were admitted to one of the participating hospitals (Gifu Prefectural
General Medical Center and Gifu Prefectural Tajimi Hospital in Gifu
Prefecture, Japan; and Hirosaki University Hospital, Reimeikyo
Rehabilitation Hospital, and Hirosaki Stroke Center in Aomori
Prefecture, Japan) between October 2002 and March 2008 because
of various symptoms or for an annual health checkup, or who were
recruited to a population-based prospective cohort study of aging and
age-related diseases in Gunma Prefecture and Tokyo, Japan.
Diagnosis of metabolic syndrome was based on a modiﬁed version
of the deﬁnition proposed by the America Heart Association and the U.
S. National Heart, Lung, and Blood Institute [4]. In this modiﬁed
version, which was also used in the West of Scotland Coronary
Prevention Study [39] and the Women's Health Study [40], waist
circumference is replaced by body mass index (BMI). On the basis ofTable 4
Effects of genotypes and other characteristics on the prevalence of chronic kidney
disease as determined by a stepwise forward selection procedure (Pb0.05) among
individuals with metabolic syndrome
Variable P R2
Age b0.0001 0.0370
Diabetes mellitus b0.0001 0.0211
Hypertension b0.0001 0.0103
APOE (TT versus GG+GT) 0.0006 0.0056
ABCA1 (TT versus CC+CT) 0.0058 0.0036
PTGS1 (TT versus CC+CT) 0.0097 0.0032
TNF (AA+CA versus CC) 0.0117 0.0031
CPB2 (AA+GA versus GG) 0.0250 0.0024
AGTR1 (AA+GA versus GG) 0.0256 0.0023
OR13G1 (GG+AG versus AA) 0.0293 0.0022
GNB3 (TT versus CC+CT) 0.0314 0.0022
ABCA1 (GG versus AA+AG) 0.0327 0.0022the recent recognition of a need to revise BMI criteria for obesity in
Japanese and other Asian populations [41], we set the cutoff point for
obesity as a BMI of ≥25 kg/m2. The 2150 study subjects withmetabolic
syndrome thus had three or more of the following ﬁve components of
this condition: (1) a BMI of ≥25 kg/m2; (2) a serum triglyceride
concentration of ≥1.65 mmol/L (150 mg/dL) or drug treatment for
elevated triglyceride; (3) a serum HDL-cholesterol concentration of
b1.04 mmol/L (40 mg/dL) for men or b1.30 mmol/L (50 mg/dL) for
women, or drug treatment for low HDL-cholesterol; (4) a systolic
blood pressure of ≥130mmHg, diastolic blood pressure of ≥85mmHg,
or drug treatment for hypertension; and (5) a fasting plasma glucose
level of ≥5.50 mmol/L (100 mg/dL) or drug treatment for high glucose.
Estimated glomerular ﬁltration rate (eGFR) was calculated with
the use of the simpliﬁed prediction equation proposed by the
Japanese Society of Nephrology and based on that described in the
Modiﬁcation of Diet in Renal Disease (MDRD) Study [42]: eGFR
(mL min−1 1.73 m−2)=194×[age (years)]−0.287×[serum creatinine
(mg/dL)]−1.094 [×0.739 (if female)]. The National Kidney Founda-
tion–Kidney Disease Outcomes Quality Initiative guidelines have
proposed that CKD be diagnosed if eGFR is b60 mL min−11.73 m−2 [1].
Previous observations have demonstratednonlinear relations between
GFR and the risk of adverse events, such as death, cardiovascular
events, and hospitalization, with an increased risk associated with an
eGFR of b60 mL min−1 1.73 m−2 and a markedly increased risk
associated with values of b45 mL min−11.73 m−2 [43]. In addition, the
rate of GFR decline was signiﬁcantly higher in Japanese individuals
younger than 70 yearswhohad an initial GFRof b50mLmin−11.73m−2
[44]. We thus adopted an eGFR of b50 mL min−1 1.73 m−2 as the
criterion for CKD in the present study. On the basis of this criterion, 411
subjects (256men,155women)were diagnosedwith CKD. The control
subjects comprised 1739 individuals (1050 men, 689 women) whose
eGFR was ≥60 mL min−1 1.73 m−2. The study protocol complied with
the Declaration of Helsinki and was approved by the Committees on
the Ethics of Human Research of Mie University Graduate School of
Medicine, Hirosaki University Graduate School of Medicine, Gifu
International Institute of Biotechnology, Tokyo Metropolitan Institute
of Gerontology, and participating hospitals. Written informed consent
was obtained from each participant.
Selection of polymorphisms
Our aim was to identify genes associated with CKD in Japanese
individuals with metabolic syndrome in a case-control association
study by examining the relations of one to four polymorphisms of
each candidate gene to this condition. With the use of public
databases, including PubMed (NCBI) and Online Mendelian Inheri-
tance in Man (OMIM), we selected 80 candidate genes that have been
characterized and suggested to be associatedwith CKD. On the basis of
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polymorphism (SNP) databases [dbSNP (NCBI) and Japanese SNP
(JSNP)], we further selected 100 polymorphisms of these genes, most
located in the promoter region or exons, that might be expected to
result in changes in the function or expression of the encoded protein
(Supplementary Table 2).
Genotyping of polymorphisms
Venous blood (7mL)was collected into tubes containing50mmol/L
ethylenediaminetetraacetic acid (disodium salt), and genomic DNA
was isolated with a kit (Genomix; Talent, Trieste, Italy). Genotypes of
the 100 polymorphisms were determined at G&G Science (Fukushima,
Japan) by amethod that combines the polymerase chain reaction (PCR)
and sequence-speciﬁc oligonucleotide probes with suspension array
technology (Luminex, Austin, TX). Primers, probes, and other PCR
conditions for genotyping polymorphisms found to be related (P value
for allele frequency of b0.05) to CKD by the chi-square test are shown
in Supplementary Table 3. Detailed genotyping methodology was
described previously [45].
Statistical analysis
Quantitative data were compared between subjects with CKD and
controls by the unpaired Student's t test. Categorical data were
compared by the chi-square test. Allele frequencies were estimated by
the gene counting method, and the chi-square test was used to
identify departures from Hardy-Weinberg equilibrium. In the initial
screen, the genotype distribution (3×2) and allele frequencies (2×2)
of each polymorphism were compared between subjects with CKD
and controls by the chi-square test. Given the multiple comparisons of
genotypes with CKD, the FDRwas calculated from the distribution of P
values for the allele frequencies of the 100 polymorphisms [46].
Polymorphisms with a P value of b0.05 for allele frequency were
further examined by multivariable logistic regression analysis with
adjustment for covariates. Such analysis was thus performedwith CKD
as a dependent variable and independent variables including age, sex
(0=woman, 1=man), history of hypertension, diabetes mellitus, or
hypercholesterolemia (0=no history, 1=positive history), and geno-
type of each polymorphism; the P value, odds ratio, and 95%
conﬁdence interval were calculated. Each genotype was assessed
according to dominant (0=major allele homozygote, 1=heterozygo-
te=minor allele homozygote), recessive (0=major allele homozygo-
te=heterozygote, 1=minor allele homozygote), and additive [(0, 0)=
major allele homozygote, (1, 0)=heterozygote, (0, 1)=minor allele
homozygote] genetic models. Additive models included the additive 1
model (heterozygotes versus major allele homozygotes) and the
additive 2 model (minor allele homozygotes versus major allele
homozygotes), which were analyzed simultaneously with a single
statistical model. We also performed a stepwise forward selection
procedure to examine the effects of genotypes as well as of other
covariates on CKD. In this analysis, each genotype was examined
according to a dominant or recessive model on the basis of statistical
signiﬁcance in the multivariable logistic regression analysis. The P
levels for inclusion in and exclusion from the model were 0.25 and 0.1,
respectively. With the exception of the initial screen by the chi-square
test (FDRb0.05), a P value of b0.05 was considered statistically
signiﬁcant. Statistical signiﬁcance was examined by two-sided tests
performed with JMP version 6.0 and JMP Genomics version 3.2
software (SAS Institute, Cary, NC).
Acknowledgments
In addition to the authors, the following investigators participated
in the study: H. Matsuo and T. Segawa (Gifu Prefectural General
Medical Center); T. Hibino, K. Yajima, and T. Kawamiya (GifuPrefectural Tajimi Hospital); and A. Yasunaga, H. Park, and N. Fuku
(Tokyo Metropolitan Institute of Gerontology). We also thank the
nursing and laboratory staff of the participating hospitals.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2008.11.001.
References
[1] National Kidney Foundation, K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classiﬁcation, and stratiﬁcation, Am. J. Kidney Dis. 39
(suppl 1) (2002) S1–S266.
[2] D.E. Weiner, et al., Chronic kidney disease as a risk factor for cardiovascular disease
and all-cause mortality: a pooled analysis of community-based studies, J. Am. Soc.
Nephrol. 15 (2004) 1307–1315.
[3] T.H. Jafar, et al., Progression of chronic kidney disease: the role of blood pressure
control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-
level meta-analysis, Ann. Intern. Med. 139 (2003) 244–252.
[4] S.M. Grundy, et al., Diagnosis and management of the metabolic syndrome: an
American Heart Association/National Heart, Lung, and Blood Institute Scientiﬁc
Statement, Circulation 112 (2005) 2735–2752.
[5] H. Tanaka, Y. Shiohira, Y. Uezu, A. Higa, K. Iseki, Metabolic syndrome and chronic
kidney disease in Okinawa, Japan, Kidney Int. 69 (2006) 369–374.
[6] J. Chen, et al., The metabolic syndrome and chronic kidney disease in U.S. adults,
Ann. Intern. Med. 140 (2004) 167–174.
[7] T. Ninomiya, et al., Metabolic syndrome and CKD in a general Japanese population:
the Hisayama Study, Am. J. Kidney Dis. 48 (2006) 383–391.
[8] H.M. Lakka, et al., The metabolic syndrome and total and cardiovascular disease
mortality in middle-aged men, JAMA 288 (2002) 2709–2716.
[9] A.M. McNeill, et al., The metabolic syndrome and 11-year risk of incident
cardiovascular disease in the atherosclerosis risk in communities study, Diabetes
Care 28 (2005) 385–390.
[10] B. Boden-Albala, et al., Metabolic syndrome and ischemic stroke risk: Northern
Manhattan Study, Stroke 39 (2008) 30–35.
[11] R.M. Najarian, et al., Metabolic syndrome compared with type 2 diabetes mellitus
as a risk factor for stroke: the Framingham Offspring Study, Arch. Intern. Med. 166
(2006) 106–111.
[12] R.W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role
in cell biology, Science 240 (1988) 622–630.
[13] U. Beisiegel, et al., The LDL-receptor-related protein, LRP, is an apolipoprotein E-
binding protein, Nature 341 (1989) 162–164.
[14] C. Ehnholm, M. Lukka, T. Kuusi, E. Nikkilä, G. Utermann, Apolipoprotein E
polymorphism in the Finnish population: gene frequencies and relation to
lipoprotein concentrations, J. Lipid Res. 27 (1986) 227–235.
[15] C.F. Sing, J. Davignon, Role of the apolipoprotein E polymorphism in determining
normal plasma lipid and lipoprotein variation, Am. J. Hum. Genet. 37 (1985)
268–285.
[16] M. Xhignesse, S. Lussier-Cacan, C.F. Sing, A.M. Kessling, J. Davignon, Inﬂuences of
common variants of apolipoprotein E onmeasures of lipidmetabolism in a sample
selected for health, Arterioscler. Thromb. 11 (1991) 1100–1110.
[17] P.W. Wilson, et al., Apolipoprotein E alleles, dyslipidemia, and coronary heart
disease. The Framingham Offspring Study, JAMA 272 (1994) 1666–1671.
[18] F.M. van Bockxmeer, C.D. Mamotte, Apolipoprotein epsilon 4 homozygosity in
young men with coronary heart disease, Lancet 340 (1992) 879–880.
[19] C. Lahoz, et al., Apolipoprotein E genotype and cardiovascular disease in the
Framingham Heart Study, Atherosclerosis 154 (2001) 529–537.
[20] Y. Song, M.J. Stampfer, S. Liu, Meta-analysis: apolipoprotein E genotypes and risk
for coronary heart disease, Ann. Intern. Med. 141 (2004) 137–147.
[21] C.C. Hsu, et al., Apolipoprotein E and progression of chronic kidney disease, JAMA
293 (2005) 2892–2899.
[22] H. Kimura, et al., Apolipoprotein E4 reduces risk of diabetic nephropathy in
patients with NIDDM, Am. J. Kidney Dis. 31 (1998) 666–673.
[23] H. Oda, N. Yorioka, C. Ueda, S. Kushihata, M. Yamakido, Apolipoprotein E
polymorphism and renal disease, Kidney Int. 56 (suppl 71) (1999) S25–S27.
[24] J.C. Lambert, et al., Independent association of an APOE gene promoter
polymorphism with increased risk of myocardial infarction and decreased APOE
plasma concentrations—the ECTIM study, Hum. Mol. Genet. 9 (2000) 57–61.
[25] A. Hirashiki, et al., Association of gene polymorphisms with coronary artery
disease in low- or high-risk subjects deﬁned by conventional risk factors, J. Am.
Coll. Cardiol. 42 (2003) 1429–1437.
[26] B.L. Kasiske, Relationship between vascular disease and age-associated changes in
the human kidney, Kidney Int. 31 (1987) 1153–1159.
[27] W.F. Keane, B.L. Kasiske, M.P. O ' Donnell, Lipids and progressive glomerulo-
sclerosis. A model analogous to atherosclerosis, Am. J. Nephrol. 8 (1988) 261–271.
[28] T. Harada, A common Ile 823 Met variant of ATP-binding cassette transporter A1
gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese
population, Atherosclerosis 169 (2003) 105–112.
[29] U. Hodoğlugil, D.W. Williamson, Y. Huang, R.W. Mahley, Common polymorphisms
of ATP binding cassette transporter A1, including a functional promoter
polymorphism, associated with plasma high density lipoprotein cholesterol levels
in Turks, Atherosclerosis 183 (2005) 199–212.
226 T. Yoshida et al. / Genomics 93 (2009) 221–226[30] Y. Suwazono, et al., G-protein beta 3 subunit polymorphism C1429T and low-
density lipoprotein receptor-related protein 5 polymorphism A1330V are risk
factors for hypercholesterolemia in Japanese males — a prospective study over
5 years, Metabolism 55 (2006) 751–757.
[31] C.R. Lee, et al., Cyclooxygenase polymorphisms and risk of cardiovascular events:
the Atherosclerosis Risk in Communities (ARIC) study, Clin. Pharmacol. Ther. 83
(2008) 52–60.
[32] I. Juhan-Vague, et al., Plasma thrombin-activatable ﬁbrinolysis inhibitor antigen
concentration and genotype in relation to myocardial infarction in the north and
south of Europe, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 867–873.
[33] D. Shiffman, et al., Identiﬁcation of four gene variants associated with myocardial
infarction, Am. J. Hum. Genet. 77 (2005) 596–605.
[34] C.C. Hsu, et al., Genetic variation of the renin-angiotensin system and chronic
kidney disease progression in black individuals in the atherosclerosis risk in
communities study, J. Am. Soc. Nephrol. 17 (2006) 504–512.
[35] E. Coll, B. Campos, D. González-Núñez, A. Botey, E. Poch, Association between the
A1166C polymorphism of the angiotensin II receptor type 1 and progression of
chronic renal insufﬁciency, J. Nephrol. 16 (2003) 357–364.
[36] D. Thibaudin, et al., TNFA2 and d2 alleles of the tumor necrosis factor alpha gene
polymorphism are associated with onset/occurrence of idiopathic membranous
nephropathy, Kidney Int. 71 (2007) 431–437.
[37] M. Buraczynska, P. Mierzicki, K. Buraczynska, M. Dragan, A. Ksiazek, Tumor
necrosis factor-alpha gene polymorphism correlates with cardiovascular disease
in patients with end-stage renal disease, Mol. Diagn. Ther. 11 (2007) 257–263.[38] Y. Yamada, S. Ichihara, H. Izawa, M. Tanaka, M. Yokota, Genetic risk for coronary
artery disease in individuals with or without type 2 diabetes, Mol. Genet. Metab.
81 (2004) 282–290.
[39] N. Sattar, et al., Metabolic syndrome with and without C-reactive protein as a
predictor of coronary heart disease and diabetes in the West of Scotland Coronary
Prevention Study, Circulation 108 (2003) 414–419.
[40] P.M. Ridker, J.E. Buring, N.R. Cook, N. Rifai, C-reactive protein, the metabolic
syndrome, and risk of incident cardiovascular events: an 8-year follow-up of
14719 initially healthy American women, Circulation 107 (2003) 391–397.
[41] M. Kanazawa, et al., Criteria and classiﬁcation of obesity in Japan and Asia-
Oceania, Asia Pac. J. Clin. Nutr. 11 (suppl 8) (2002) S732–S737.
[42] E. Imai, et al., Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and
methods, Hypertens. Res. 31 (2008) 1101–1107.
[43] A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu, Chronic kidney disease and
the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med. 351
(2004) 1296–1305.
[44] E. Imai, et al., Slower decline of glomerular ﬁltration rate in the Japanese general
population: a longitudinal 10-year follow-up study, Hypertens. Res. 31 (2008)
433–441.
[45] Y. Itoh, et al., High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a
PCR-SSOP-Luminex method in the Japanese population, Immunogenetics 57
(2005) 717–729.
[46] Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: a practical and
powerful approach tomultiple testing, J. Royal Stat. Soc. Ser. B. 57 (1995) 289–300.
